TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04865835

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: single dose of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-363856
Description: single dose of SEP 363856 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: metformin-HCl 850 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: metformin
Description: metformin-HCl 850 mg
Study: NCT05639088

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transition preparation program
Description: AYA will participate in virtual or in-person sessions with a transition coach and receive bi-weekly messages that encourage self-management.~Caregivers will attend a virtual or in-person session with a transition coach.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Educational materials
Description: AYA and caregivers will receive educational materials regarding healthcare transition and diabetes management monthly for 6 months
Study: NCT05682482

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LT3 (liothyronine)
Description: Addition of liothyronine (LT4/LT3 combination therapy) in patients with persistent tiredness on LT4 monotherapy. To investigate whether addition of LT3 is effective in relieving tiredness.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Addition of placebo (LT4 monotherapy) in patients with persistent tiredness on LT4 monotherapy.
Study: NCT05391217

Intervention type: OTHER
Intervention: Remote assessment of patient reported outcomes and daily activity
Description: Electronic patient-reported outcomes (NIH PROMIS) will be collected and combined with remotely monitored physical activity, heart rate, and sleep, as measured with a Fitbit (Sense).
Study: NCT06022406

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMT capsules
Description: Formulation: 80-100g of healthy donor stool processed, frozen and encapsulated in gelatin capsules (modified Kao et al, 2017).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: Formulation: microcrystalline cellulose, for equivalence in weight and color, will be encapsulated in gelatin capsules. Each capsule will be filled with approximatively 5.5g of microcrystalline cellulose, and encapsulated in size 0 and size 00 capsules.
Study: NCT05560594

Intervention type: DEVICE
Group type: OTHER
Intervention: Coloplast SpeediCath CH12 standard male intermittent catheter
Description: Drainage of the bladder through the urethra when using the SpeediCath standard male intermittent catheter.
Study: NCT06199518

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transperitoneal laparoscopic ureterolithotomy (T-LUL)/ retrograde flexible ureteroscopy (R-URS) /Antegrade mini-percutaneous flexible ureteroscopy (A-URS)
Description: extraction or fragmentation of large proximal ureteral stones via different minimally invasive procedures

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transperitoneal laparoscopic ureterolithotomy (T-LUL)/ retrograde flexible ureteroscopy (R-URS) /Antegrade mini-percutaneous flexible ureteroscopy (A-URS)
Description: extraction or fragmentation of large proximal ureteral stones via different minimally invasive procedures

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transperitoneal laparoscopic ureterolithotomy (T-LUL)/ retrograde flexible ureteroscopy (R-URS) /Antegrade mini-percutaneous flexible ureteroscopy (A-URS)
Description: extraction or fragmentation of large proximal ureteral stones via different minimally invasive procedures
Study: NCT04874311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa
Description: Bintrafusp alfa will be administered by intravenous infusion on day 1 every 3 weeks at a fixed dose of 2400 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa
Description: Bintrafusp alfa will be administered by intravenous infusion on day 1 every 3 weeks at a fixed dose of 2400 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin will be administered by intravenous infusion on day 1 every 3 weeks at a fixed dose of 75 mg/m² for a maximum of 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin will be administered by intravenous infusion on day 1 every 3 weeks at a fixed dose of 75 mg/m² for a maximum of 6 cycles

Intervention type: DRUG
Group type: OTHER
Intervention: Doxorubicin
Description: Doxorubicin will be administered by intravenous infusion on day 1 every 3 weeks at a fixed dose of 75 mg/m² for a maximum of 6 cycles

Intervention type: DRUG
Group type: OTHER
Intervention: Doxorubicin
Description: Doxorubicin will be administered by intravenous infusion on day 1 every 3 weeks at a fixed dose of 75 mg/m² for a maximum of 6 cycles
Study: NCT05059457

Intervention type: DEVICE
Intervention: Blood source: single and pooled capillary and venous blood
Description: * A single drop of capillary blood (blood drop #3) will be placed in a microcuvette directly from a finger/heel and tested using a HemoCue 201+.~* Pooled capillary blood will be placed in a Microtainer® tube (250-500 µL) containing EDTA and then a drop of blood placed in a microcuvette and tested using a HemoCue 201+.~* Venous blood will be collected into a 3mL Vacutainer tube containing EDTA and then a drop of blood will be placed in a microcuvette and tested using a HemoCue 201+ and autoanalyzer.

Intervention type: DEVICE
Intervention: Blood source: single capillary and venous blood
Description: * A single drop of capillary blood (blood drop #3) will be placed in a microcuvette directly from a finger/heel and tested using a HemoCue 201+ .~* Venous blood will be collected into a 3mL Vacutainer tube containing EDTA and then a drop of blood will be placed in a microcuvette and tested using a HemoCue 201+ and autoanalyzer.

Intervention type: DEVICE
Intervention: Blood source: pooled capillary and venous blood
Description: * Pooled capillary blood will be placed in a Microtainer® tube (250-500 µL) containing EDTA and then a drop of blood placed in a microcuvette and tested using a HemoCue 201+.~* Venous blood will be collected into a 3mL Vacutainer tube containing EDTA and then a drop of blood will be placed in a microcuvette and tested using a HemoCue 201+ and autoanalyzer.
Study: NCT06292143

Intervention type: OTHER
Group type: OTHER
Intervention: Advance Care Planning Toolkit
Description: Participants or their caregivers will access the digital platform for advance care planning
Study: NCT05809895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ociperlimab
Description: 900 mg intravenously (IV) every 3 weeks (Q3W)

Intervention type: DRUG
Group type: OTHER
Intervention: Ociperlimab
Description: 900 mg intravenously (IV) every 3 weeks (Q3W)
Study: NCT06566638

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NucleoCapture device
Description: 100ml NucleoCapture selective DNA adsorber.
Study: NCT06565767

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cardiopulmonary resuscitation quality
Description: variability in compression depth among different age groups, taking into account physical attributes, through an active learning approach and game-based learning framework

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cardiopulmonary resuscitation quality
Description: variability in compression depth among different age groups, taking into account physical attributes, through an active learning approach and game-based learning framework
Study: NCT05460377

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Full dose Sabin Inactivated Poliovirus Vaccine produced by IMBCAMS
Description: The Sabin antigen content is 30, 32 and 45 D-antigen units (DU) for types 1, 2 and 3, respectively and will be delivered intramuscularly by needle and syringe.
Study: NCT05809895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200 mg intravenously (IV) Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tislelizumab
Description: 200 mg intravenously (IV) Q3W

Intervention type: DRUG
Group type: OTHER
Intervention: Tislelizumab
Description: 200 mg intravenously (IV) Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 90 mg/m2 intravenously (IV) on Days 1, 8 and 15 every 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 90 mg/m2 intravenously (IV) on Days 1, 8 and 15 every 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 90 mg/m2 intravenously (IV) on Days 1, 8 and 15 every 28 days

Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: 90 mg/m2 intravenously (IV) on Days 1, 8 and 15 every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: 100 mg/m2 intravenously (IV) on Days 1, 8 and 15 every 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: 100 mg/m2 intravenously (IV) on Days 1, 8 and 15 every 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: 100 mg/m2 intravenously (IV) on Days 1, 8 and 15 every 28 days

Intervention type: DRUG
Group type: OTHER
Intervention: Nab-paclitaxel
Description: 100 mg/m2 intravenously (IV) on Days 1, 8 and 15 every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 2 intravenously (IV) on Days 1 and 8 every 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: AUC 2 intravenously (IV) on Days 1 and 8 every 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: AUC 2 intravenously (IV) on Days 1 and 8 every 21 days

Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin
Description: AUC 2 intravenously (IV) on Days 1 and 8 every 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: normal saline intravenously (IV) Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: normal saline intravenously (IV) Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: 200 mg intravenously (IV) Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 intravenously (IV) on Days 1 and 8 every 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1000 mg/m2 intravenously (IV) on Days 1 and 8 every 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1000 mg/m2 intravenously (IV) on Days 1 and 8 every 21 days

Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine
Description: 1000 mg/m2 intravenously (IV) on Days 1 and 8 every 21 days
Study: NCT05460377

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fractional (1/5) Dose Sabin Inactivated Poliovirus Vaccine produced by IMBCAMS
Description: The Sabin antigen content is 30, 32 and 45 D-antigen units (DU) for types 1, 2 and 3, respectively and will be delivered intradermally by needle and syringe.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Full dose Sabin Inactivated Poliovirus Vaccine produced by BIBP
Description: The Sabin antigen content is 15 DU, 45 DU, 45 DU for types 1, 2, and 3, respectively and will be delivered intramuscularly by needle and syringe

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fractional (1/5) dose Sabin Inactivated Poliovirus Vaccine produced by BIBP
Description: The Sabin antigen content is 15 DU, 45 DU, 45 DU for types 1, 2, and 3, respectively and will be delivered intradermally by needle and syringe
Study: NCT05564533

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart-Smile Training Intensive Introduction Program (HST-IIP)
Description: Heart-Smile Training (HST) is an interoceptive compassion program designed to develop the qualities of compassion, empathy, and kindness for oneself and others with a focus on interoceptive awareness. It is unique from other compassion trainings in its focus on 1) embodiment of warmth and tenderness of compassionate feeling with a compassionate body scan meditation, 2) development of an authentic presence, characterized by a warm feeling of loosened attachment to ego-based self, and 3) cultivation of joy triggered by genuine smile to oneself. HST-IIP is a 3-day/4-week/1-day interoceptive compassion program that shares the same core elements and practices as HST 3-day intensive program. Unlike HST, the format of the HST-IIP has an extended duration to develop self-regulation through the cultivation of emotional and behavioral regulation.
Study: NCT05645016

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COEST
Description: Adapted version of our COEST training, targeting Black church members.
Study: NCT06556576

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IMPROVA Platform
Description: Adolescents, teachers, school staff, and parents will have access to a variety of content aimed at promoting the mental health and well-being of adolescents that can be accessed through the IMPROVA platform, an innovative eHealth solution that can be accessed via app and website.~Students: around 20 modules that can be grouped in five categories: Me and My Emotions, Me and My Body, Me and My Relationships, School and Free time, and Finding my Strengths.~Teachers and other school staff: 1) pedagogical and health-related modules to support their students and teaching practices; 2) modules to manage their own health; 3) tutoring sessions: resources (lessons plans) for tutors (teachers or other school staff) for carrying out a discussion with students in topics related to the students' health and wellbeing.~Parents: contents on promoting positive relationships, emotional and social skills, positive behaviour, behaviours to support wellbeing, and family-school collaboration.
Study: NCT05068700

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Integrated Pulmonary Index
Description: Medtronic Capnostream 35p monitoring parameter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard capnography monitoring
Description: Medtronic Capnostream 35p monitoring parameter
Study: NCT05434767

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile application
Description: Participants will be instructed on the installation and use of the mobile application on their personal mobile phones. Participants will then have to perform the assigned exercises using the mobile application 3 times daily. Physiotherapists will still perform the required assessment/review, education, and intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard rehabilitation program
Description: All participants will be seen by physiotherapists in the ward post-TKR surgery and undergo standard inpatient rehabilitation. Patients will be given instructions to perform assigned exercises 3 times daily. Physiotherapists will perform the required assessment/review, education, and intervention.
Study: NCT05156164

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio Tape Group
Description: The application of the KT consists of 6 strips of I-shaped tape adhered to the skin areas of the shoulder

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control Group
Description: KT application on the deltoid but without support function
Study: NCT05661071

Intervention type: OTHER
Intervention: Modified Mini Mental Test:
Description: To assess the cognitive function of children

Intervention type: OTHER
Intervention: Modified Mini Mental Test:
Description: To assess the cognitive function of children

Intervention type: OTHER
Intervention: The Controlled Oral Word Association Test
Description: To assess the cognitive function of children

Intervention type: OTHER
Intervention: The Controlled Oral Word Association Test
Description: To assess the cognitive function of children

Intervention type: OTHER
Intervention: The Central Nervous System Vital Signs
Description: To assess the cognitive function of children

Intervention type: OTHER
Intervention: The Central Nervous System Vital Signs
Description: To assess the cognitive function of children

Intervention type: OTHER
Intervention: Conners' Parent Rating Scale-48 (Parent Report)
Description: To assess attention-deficit/hyperactivity disorder

Intervention type: OTHER
Intervention: Conners' Parent Rating Scale-48 (Parent Report)
Description: To assess attention-deficit/hyperactivity disorder

Intervention type: OTHER
Intervention: Child Behavior Checklist 6-18 ages (Parent Report)
Description: To assesses both child adaptive behaviors and problem behaviors.

Intervention type: OTHER
Intervention: Child Behavior Checklist 6-18 ages (Parent Report)
Description: To assesses both child adaptive behaviors and problem behaviors.

Intervention type: OTHER
Intervention: Strengths and Difficulties Questionnaire (Self-Reported)
Description: It is a brief emotional and behavioural screening questionnaire for children and young people.

Intervention type: OTHER
Intervention: Strengths and Difficulties Questionnaire (Self-Reported)
Description: It is a brief emotional and behavioural screening questionnaire for children and young people.

Intervention type: OTHER
Intervention: Brooke Lower Extremity Functional Classification
Description: To determine the functional status of the lower extremity

Intervention type: OTHER
Intervention: Motor Function Measurement-32 Items
Description: To assessment of motor function and progression of weakness in neuromuscular disorders

Intervention type: OTHER
Intervention: Four Square Step Test
Description: A test of dynamic balance and coordination that clinically assesses the participant's ability to step over objects forward, sideways, and backwards.

Intervention type: OTHER
Intervention: Six Minutes Walk Test
Description: It evaluates the walking function and physical capacity of children at the submaximal level.

Intervention type: OTHER
Intervention: Timed Performance Test
Description: 10 meters Walk\& Run Test, Gower's(from a supine to a standing position), Right\& Left Leg Standing, Ascent/Descent of 4 Steps
Study: NCT05285943

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olive oil cream
Description: Olive oil prepared in a base cream to be applied to irradiated areas.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone Valerate Cream
Description: Betamethasone valerate prepared in a base cream to be applied to irradiated areas.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Base Cream
Description: The base cream used for preparation of both the betamethasone valerate cream and olive cream will be used as a placebo control to be applied to irradiated areas.
Study: NCT06567756

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CSPO
Description: The distal rectum is freed to the entrance of the internal and external sphincter space, and then an oblique resection line is designed under direct vision according to the tumor site and shape, ensuring that the distal and lateral margins are not less than 1 cm, and preserving the contralateral dentate line and the intestinal wall as much as possible, and the anastomosis is completed manually or with instruments.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ISR
Description: Partial, subtotal, or total excision of the internal sphincter and/or a portion of the longitudinal rectal muscle, expansion of the distal rectal excision margin into the anal canal or to the anal verge, and completion of the colo-anal anastomosis manually or instrumentally.
Study: NCT04980417

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: concomitant cholecystectomy
Description: delayed cholecystectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: concomitant cholecystectomy
Description: delayed cholecystectomy
Study: NCT06646536

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anti-gravity treadmill training
Description: Patients will participate to anti-gravity treadmill (Alter G) walking program in addition to physiotherapy and rehabilitation program for 6 weeks, 2 days a week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treadmill training
Description: Patients will participate to walking program on a standard treadmill in addition to physiotherapy and rehabilitation program for 6 weeks, 2 days a week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard physiotherapy and rehabilitation program
Description: Patients will participate to physiotherapy and rehabilitation program for 6 weeks, 2 days a week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard physiotherapy and rehabilitation program
Description: Patients will participate to physiotherapy and rehabilitation program for 6 weeks, 2 days a week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard physiotherapy and rehabilitation program
Description: Patients will participate to physiotherapy and rehabilitation program for 6 weeks, 2 days a week.
Study: NCT05079204

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intra oral scan
Description: Cover key details of the intervention. Must be sufficiently detailed to distinguish between arms of a study and/or among similar interventions Intervention consists in an 3D intra oral representation of the oral cavity.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Description: No intervention
Study: NCT05898009

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: blood sample for BRCA2 mutation detection
Description: blood sample
Study: NCT06647576

Intervention type: DEVICE
Intervention: Spinal Cord Stimulation - In Clinic
Description: Control Group Intervention: In-Person SCS therapy. Device settings, such as pulse width and frequency, will be adjusted during regular clinic visits. Follow-up assessments for pain relief, quality of life, and therapy effectiveness will occur at 1, 3, and 6-month intervals over a 6-month period.

Intervention type: DEVICE
Intervention: Spinal Cord Stimulation - Neurosphere
Description: Test Group Intervention: Test group participants will receive remote monitoring and therapy adjustments through the Neurosphere™ virtual clinic platform. Participants in test group will have trial and end of trial phases in clinic, but further SCS therapy will be performed through Neurosphere. Clinicians will adjust the SCS device settings, including pulse width and burst frequency, remotely. This intervention allows patients to avoid in-person visits while receiving continuous, personalized care, with follow-up assessments at 1, 3, and 6 months over a 6-month period.
Study: NCT05604209

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C62
Description: C62 administered at Day 0 and M4 on Day 28

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C1C62
Description: C1C62 administered at Day 0 and M3M4 on Day 28

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered on Day 0 and 28

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M4
Description: M4 administered at Day 28

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M3M4
Description: M3M4 administered on Day 28